Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro by unknown
Ouyang et al. Chin Med  (2016) 11:11 
DOI 10.1186/s13020-016-0083-z
RESEARCH
Kinetics of cytochrome P450 enzymes 
for metabolism of sodium tanshinone IIA 
sulfonate in vitro
Dong‑sheng Ouyang1,2, Wei‑hua Huang1, Dan Chen1, Wei Zhang1, Zhi‑rong Tan1, Jing‑bo Peng1, 
Yi‑cheng Wang2, Ying Guo2, Dong‑li Hu2, Jian Xiao3 and Yao Chen1,2*
Abstract 
Background: Sodium tanshinone IIA sulfonate (STS) is a water‑soluble derivative of tanshinone IIA for treating cardio‑
vascular disorders. The roles of cytochrome P450 enzymes (CYPs) in the metabolism of STS have remained unclear. 
This study aims to screen the main CYPs for metabolism of STS and study their interactions in vitro.
Methods: Seven major CYPs were screened for metabolism of STS by human liver microsomes (HLMs) or recombi‑
nant CYP isoforms. Phenacetin (CYP1A2), coumarin (CYP2A6), tolbutamide (CYP2C9), metoprolol (CYP2D6), chlorzoxa‑
zone (CYP2E1), S‑mephenytoin (CYP2C19), and midazolam (CYP3A4) were used as probe substrates to determine the 
potential of STS in affecting CYP‑mediated phase I metabolism in humans. Enzyme kinetic studies were performed to 
investigate the modes of inhibition of the enzyme–substrate interactions by GraphPad Prism Enzyme Kinetic 5 Demo 
software.
Results: Sodium tanshinone IIA sulfonate inhibited the activity of CYP3A4 in a dose–dependent manner by the 
HLMs and CYP3A4 isoform. The Km and Vmax values of STS were 54.8 ± 14.6 µM and 0.9 ± 0.1 nmol/mg protein/min, 
respectively, for the HLMs and 7.5 ± 1.4 µM and 6.8 ± 0.3 nmol/nmol P450/min, respectively, for CYP3A4. CYP1A2, 
CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP2C19 showed minimal or no effects on the metabolism of STS.
Conclusion: This in vitro study showed that STS mainly inhibited the activities of CYP3A4.
© 2016 Ouyang et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Tanshinone IIA (Fig. 1a) is one of the main extracts from 
Salvia miltiorrhiza (Danshen) for treating cardiovas-
cular disorders [1]. Tanshinone IIA is the most effec-
tive fat-soluble monomer extracted from Danshen, with 
anti-inflammatory [2], antitumor [3], antioxidative [4, 
5], and antiplatelet aggregation activities [6, 7]. How-
ever, as clinical use of tanshinone IIA is limited by its 
poor water solubility, sodium tanshinone IIA sulfonate 
(STS) (Fig.  1b) has been developed through sulfonation 
with greater water-soluble characteristics and efficacies 
than tanshinone IIA [8], and has been used in injection 
with typical doses of 40–80 mg/d for cardioprotective [9, 
10], anti-cardiomyocyte hypertrophy [11], and antiviral 
effects [12–14]. To date, only several studies reported the 
pharmacokinetics parameters of STS in rats after injec-
tion. The metabolism rate of STS in rats was fast, with t1/2 
of <0.9 h, and at 4 h after the injection, the plasma con-
centration of STS in rats did not exceed 20  ng/mL [15, 
16].
CYPs comprise the most important phase I drug-
metabolizing enzyme system, and are responsible for 
the metabolism of a variety of xenobiotics [17]. Yang 
et  al. [18] reported that tanshinone (containing 20  % 
tanshinone IIA) could significantly increase (2–9.5-fold) 
the activities of CYP1A1, CYP1A2, and CYP2B1, while 
inhibiting (1.9-fold) the activity of CYP2E1 in rats. Ueng 
et  al. [19] reported that tanshinone IIA could decrease 
7-ethoxyresorufin O-deethylation (EROD) and 7-meth-
oxyresorufin O-demethylation (MROD) activities in 
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human liver microsomes (HLMs), and indicated that tan-
shinone IIA possessed the highest selectivity for inhibi-
tion of CYP1A2.The same authors further demonstrated 
that tanshinone IIA induced hepatic Cyp1A2 by increas-
ing the expression levels of Cyp1A2 mRNA and protein 
in mice [20]. Liu et al. [21] reported that CYP2A6 was the 
specific isozyme responsible for hydroxyl metabolism of 
tanshinone IIA in HLMs. Although many experiments 
related to tanshinone IIA have been performed, the ques-
tion of which CYP is responsible for the metabolism of 
STS has remained unclear.
The difference in molecular structure between STS 
and tanshinone IIA is only a sulfonic acid group at the 
C-16 position [22]. Although STS has a similar molecular 
structure to tanshinone IIA, the metabolism of STS and 
interactions with CYPs might differ from those of tan-
shinone IIA [16]. In our previous study, STS significantly 
increased the activity of CYP1A2 by 41.1  % in healthy 
volunteers [23], and the possible mechanism might be 
the induction of CYP1A2 expression by tanshinone IIA 
transformed from STS in vivo. Which CYP participated 
in the transformation of STS, and related information is 
still critical.
As CYP1A2 (13  %), CYP2A6 (4  %), CYP2D6 (2  %), 
CYP2E1 (7  %), CYP3A4 (30  %), CYP2C19 (8  %) and 
CYP2C9 (20 %) comprise 70–80 % of the hepatic CYPs in 
humans and are responsible for more than 95 % of clini-
cal drug metabolism [17]. This study aims to screen the 




Recombinant human CYP enzymes (bactosomes), 
pooled human liver microsomes (HLMs) from ten indi-
vidual donors (bactosomes), and β-nicotinamide adenine 
dinucleotide 2′-phosphate reduced tetrasodium salt 
hydrate (NADPH) were purchased from Cypex Ltd. (UK) 
and stored at −80  °C. STS (C19H17NaO6S; MW: 396.39; 
assay: ≥98 %) was obtained from Sigma-Aldrich (China). 
Furafylline (FUR), trans-2-phenylcyclopropylamine 
hydrochloride (TRA), ketoconazole (KET), sulfaphena-
zole (SUL), quinidine (QUI), chlormethiazole hydro-
chloride (CHL), and ticlopidine hydrochloride (TIC) 
were purchased from the National Institutes for Food 
and Drug Control (China). Phenacetin, coumarin, mida-
zolam, tolbutamide, S-mephenytoin, metoprolol, chlor-
zoxazone, and standards for their metabolites, including 
acetaminophen, 7-hydroxyl coumarin, 1-hydroxyl mida-
zolam, 4-hydroxyl tolbutamide, 4-hydroxyl mepheny-
toin, α-hydroxyl metoprolol, 6-hydroxyl chlorzoxazone, 
and irbesartan (internal standard) were purchased from 
Sigma-Aldrich (China). All other chemicals and sol-
vents were of high-performance liquid chromatography 
(HPLC) grade.
Apparatus and operation conditions
The concentrations of the CYP substrates and their 
metabolites were quantified using a Waters 2695 Separa-
tion Module HPLC System (Waters Corp., USA) coupled 
to a Quattro Micro™ API Triple Quadrupole Tandem 
Mass Spectrometer (Waters Corp., USA) with an elec-
trospray ionization source. The samples were separated 
on a HYPURITY C18 column (150  ×  2.1  mm; internal 
diameter: 5 µm; Thermo, USA) with a C18 security guard 
column (4.0  ×  3.0  mm; internal diameter: 5  µm). The 
mobile phase consisted of 20  mM ammonium formate 
and acetonitrile at a ratio of 60:40. Aliquots of 20  µL 
were injected at a mobile phase flow rate of 0.3 mL/min. 
Multiple reaction monitoring was performed in positive 
or negative modes according to different compounds. 
The transitions were listed in Table 1. The mass spectra 
of the metabolites formed in the incubations were iden-
tical to those of the corresponding authentic standards, 
including 7-hydrxoyl coumarin, 1- hydroxyl midazolam, 
4- hydroxyl tolbutamide, 4- hydroxyl mephenytoin, α- 
hydroxyl metoprolol, 6- hydroxyl chlorzoxazone [24].
Incubation conditions
The inhibitory effects of STS on the activities of the CYP 
isoforms were examined by HLMs (and the expressed 
CYPs, when required). The CYP isoform-specific probe 
reactions used were phenacetin O-deethylation (for 
CYP1A2), coumarin 7-hydroxylation (for CYP2A6), 
a
b
Fig. 1 Chemical structures of tanshinone IIA (a) and STS (b)
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tolbutamide 4-hydroxylation (for CYP2C9), metoprolol 
α-hydroxylation (for CYP2D6), chlorzoxazone 6-hydrox-
ylation (for CYP2E1), S-mephenytoin 4-hydroxylation 
(for CYP2C19), and midazolam 1-hydroxylation (for 
CYP3A4). The incubation mixtures consisted of substrate 
probe, HLMs (0.5  mg/mL) or CYP isoforms (10  pmol), 
and 0.1  M sodium phosphate buffer (pH 7.4) in a total 
volume of 0.2 mL that was pre-warmed for 5 min at 37 °C 
without (control) and with multiple concentrations of 
STS. Each reaction was initiated by addition of 1  mg/
mL NADPH. The final incubations were performed in a 
shaking water bath at 37 °C for 30 min. The incubations 
were performed in triple, and the incubation conditions 
specific to each CYP isoform were within the linear range 
for the velocity of the reaction (incubation time as well 
as substrate and protein concentrations). STS, probe sub-
strates, and inhibitors were dissolved in methanol, and 
the final solvent concentration in all incubations (includ-
ing controls) was 1 %. The reactions were stopped by add-
ing 0.2 mL of ice-cold acetonitrile containing irbesartan 
(114.9 ng/mL) as the internal standard. The samples were 
vortexed for 5  min. After centrifugation (5415D centri-
fuge, Eppendorf, Germany) (12,000×g for 10  min), the 
supernatants were transferred and aliquots of 20 µL were 
injected into the HPLC–MS/MS system for analysis.
Kinetic analysis of STS
Kinetic analyses were performed for STS, and the data 
generated were used as a guide for selecting the appro-
priate concentrations of STS in the subsequent inhi-
bition experiments. Thus, the kinetic parameters for 
the metabolism of STS were determined by incubating 
increasing concentrations of STS (1–100  µM) (without 
inhibitor) at 37 °C with HLMs (0.5 mg/mL) or CYP iso-
forms (10 pmol), and 0.1 M sodium phosphate buffer (pH 
7.4) in a total volume of 0.2  mL. The incubation condi-
tions consisted of substrate probe, HLMs (0.5 mg/mL) or 
CYP isoforms (10  pmol), and 0.1  M sodium phosphate 
buffer (pH 7.4) in a total volume of 0.2 mL. The equation 
for STS reaction velocity (V) by the HLMs or CYP iso-
forms was expressed as V = (C0−Ct)/T/Cp, where C0 and 
Ct represent the initial and final concentrations of STS in 
the incubation solution, respectively, T is the incubation 
time (min), and Cp is the protein concentration (mg/mL 
or nmol). All values were expressed as the mean ± stand-
ard deviation (SD). The mean intrinsic clearance rate 
(CLint) for the in vitro incubation was estimated by Vmax/
Km.
Specific CYP isoforms screened for metabolism of STS
We determined the inhibitory effects of specific inhibi-
tors on the metabolism of STS by HLMs to screen for the 
specific CYP isoform responsible for STS metabolism. 
Inhibitors including FUR (CYP1A2 inhibitor; 1  µM), 
TRA (CYP2A6 inhibitor; 1 µM), SUL (CYP2C9 inhibitor; 
1  µM), QUI (CYP2D6 inhibitor; 1  µM), CHL (CYP2E1 
inhibitor; 5  µM), TIC (CYP2C19 inhibitor; 1  µM), and 
KET (CYP3A4 inhibitor; 1  µM) were separately incu-
bated with STS (10 µM), HLMs, and NADPH under the 
same incubation conditions as mentioned above. The 
concentrations of the inhibitors used were approximately 
the same as their respective IC50 values from a previous 
report [25]. The inhibitory effects of the specific inhibi-
tors on the metabolic clearance rate (MCR) of STS were 
evaluated separately to screen for the CYP isoforms 
responsible for STS metabolism. The relative activity of 
each CYP isoform was calculated by dividing the peak 
area of STS incubated with the inhibitor by the peak area 
of STS in the negative control.
Inhibition studies for IC50 determination
A pilot inhibitory analysis of each CYP isoform was per-
formed to determine the potency of inhibition and to 
select CYP isoforms for further detailed study of their 
Table 1 Transitions and  collision energies used in  LC-MS/MS for  the detection of  the probe substrates, metabolites 
and the internal standard
Compound name Ion mode Precursor ion (m/z) Product ion (m/z) Collision energy (eV)
Sodium tanshinone IIA sulfonate Negative 373 358 20
Acetaminophen Positive 152 110 15
7‑hydroxyl coumarin Positive 162.9 107.0 20
1‑hydroxyl midazolam Positive 342 324 20
4‑hydroxyl tolbutamide Positive 287.0 171.0 15
4‑hydroxyl mephenytoin Positive 235.0 150.0 10
α‑hydroxyl metoprolol Positive 284.3 116.0 20
6‑hydroxyl chlorzoxazone Positive 195 138 20
Irbesartan (IS) Positive 429.0 206.9 22
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inhibitory activities. Various concentrations of STS 
(1–100 µM) and a single CYP isoform-specific substrate 
concentration (the Km value) were used to determine the 
inhibitory effects of STS on specific CYP isoforms. The 
substrates comprising phenacetin, coumarin, tolbuta-
mide, metoprolol, chlorzoxazone, S-mephenytoin, and 
midazolam were employed at concentrations of 10, 5, 
100, 7.5, 40, 100, and 5 µM, respectively [25]. All incuba-
tion conditions were the same as those described above. 
The inhibitory effects on the CYP isoforms were inves-
tigated individually by incubating HLMs in the absence 
or presence of STS. An incubation solution containing 
only the solvent used to dissolve STS was regarded as 
the negative control, while solutions containing only the 
specific inhibitors were regarded as positive controls. 
The IC50 values for STS were determined and compared 
with those of the specific inhibitors mentioned above 
(Table 2).
Determination of Ki
In pilot experiments (IC50 determination), STS inhib-
ited CYP3A4, while its effects on the remaining CYPs 
(CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and 
CYP2C19) were minimal. Therefore, Dixon plots for the 
inhibition of CYP3A4 were determined by incubating the 
substrate probe at multiple concentrations with or with-
out the test inhibitor at multiple concentrations with the 
HLMs and cofactors. The inhibition data obtained from 
the pilot experiments were used as a guide to generate 
appropriate probe substrate and test inhibitor concen-
trations for determination of the Ki values for each CYP 
isoform. The isoform-specific probe substrate concentra-
tions used were 5–50  µM midazolam for CYP3A4. The 
STS concentrations used were 0–100 µM.
Calculation of enzyme kinetics and statistical analysis
The MCR of the incubation solution without any specific 
inhibitor for STS was considered to be 100  % to deter-
mine the major enzymes responsible for STS metabolism 
in HLMs. The effects of the specific inhibitors on the 
MCR of STS were evaluated by one-way analysis of vari-
ance (ANOVA) (SPSS Inc., USA), LSD test was used for 
the homogeneity of variance, otherwise Tamhane’s test. 
Values of P < 0.05 denoted significance in all cases. The 
apparent kinetic parameters of STS (Km and Vmax) were 
determined by fitting the Michaelis–Menten equation 
using GraphPad Prism Enzyme Kinetic 5 Demo software 
(GraphPad Co. Ltd., USA). The equation was expressed 
as V = Vmax[S]/(Km + [S]),where Km is the substrate con-
centration at which the reaction velocity is 50 % of Vmax. 
The activity of each CYP isoform was calculated by the 
MCR of its corresponding probe substrate to determine 
the inhibition of the CYP isoforms. The MCR of the 
probe substrate was considered to be 100  % when no 
specific inhibitor and STS were added to the incubation 
assay. The IC50 values were determined by analyzing the 
plot of the logarithm of the inhibitor concentration ver-
sus the percentage of activity remaining after inhibition, 
using the SPSS for Windows Version 11.5 (SPSS Inc., 
USA). The inhibition data were fitted to different mod-
els of enzyme inhibition (competitive, noncompetitive, 
and uncompetitive) by nonlinear least-squares regression 
analysis using GraphPad Prism 5 software (GraphPad Co. 
Ltd., USA) to calculate the Ki values.
Results
Kinetic analysis of STS
The metabolism of STS after incubation with HLMs 
and CYP3A4 was shown in Fig. 2a, b. The Km and Vmax 
Table 2 IC50 and Ki values of STS against human CYP isoforms compared with that of specific inhibitors reported in litera-
ture
“–” Represents the data that is not determined
STS sodium tanshinone II A sulfonate; FUR furafylline; TRA trans-2-phenylcyclopropylamine hydrochloride; SUL sulfaphenazole; QUI quinidine; CHL chlormethiazole 
hydrochloride; TIC ticlopidine hydrochloride; KET ketoconazole; DIE diethyldithiocarbamate
a  IC50 and Ki values of specific inhibitors were referred to the reported literatures
b  Represents 95 % confidence interval





CYP1A2 Phenacetin O‑deethylation >100 FUR/1.4 [23] – FUR/3 [21]
CYP2A6 Coumarin 7‑hydroxylation >100 TRA/0.42 ± 0.07 [24] – TRA/0.17 [24]
CYP2C9 Tolbutamide 4‑hydroxylation >100 SUL/0.3–1.5 [23, 25] – SUL/0.3 [21]
CYP2D6 Metoprolol α‑hydroxylation >100 QUI/0.02–0.68 [23, 25] – SUL/0.027–0.4 [21, 26, 27]
CYP2E1 Chlorzoxazone 6‑hydroxylation >100 DIE/21.30 [23] – CHL/12 [28]
CYP2C19 S‑Mephenytoin 4‑hydroxylation >100 TCL/0.52–1.6 [25] – TCL/1.2 ± 0.5 [21]
CYP3A4 Midazolam 1‑hydroxylation 6.377 (5.536, 7.347)b KET/0.08–0.24 [21] 3.183 (0.184, 6.95)b KET/0.015 [21]
Page 5 of 9Ouyang et al. Chin Med  (2016) 11:11 
values for HLMs and CYP3A4 were 54.8  ±  14.6  µM 
and 0.9  ±  0.1  nmol/mg protein/min, respectively, and 
7.5 ± 1.4 µM and 6.8 ± 0.3 nmol/nmol P450/min, respec-
tively. The in vitro CLint values for STS with HLMs and 
CYP3A4 were 0.016 mL/mg protein/min and 0.902 mL/
nmol P450/min, respectively.
Specific CYP isoforms for the metabolism of STS
The inhibitory effects of the CYP specific inhibitors on 
the MCR of STS in HLMs were shown in Fig. 3. The con-
centrations of FUR, TRA, SUL, QUI, TIC, and KET were 
1 µM, while that of CHL was 5 µM. The concentrations 
were selected on the basis of previously reported IC50 
or Ki values for the CYP isoforms to ensure adequate 
inhibitory selectivity, and maximal inhibitory potency 
[26–29]. In the presence of KET (1  µM), the MCR of 
STS decreased to 37.4 % of that of the control. However, 
the other inhibitors had no obvious inhibitory effects 
on the metabolism of STS. The effects of the screened 
enzymes were further confirmed with human recombi-
nant CYPs using specific inhibitors, and the MCR of STS 
was decreased to 58.4 % (STS, 10 µM) and 29.4 % (STS, 
50 µM) of the control value for CYP3A4 (Fig. 4), indicat-
ing that CYP3A4 was the major enzyme responsible for 
the metabolism of STS in vitro.
a
b
Fig. 2 Concentration‑velocity curves for STS metabolism after incu‑
bation with HLMs (a) and CYP3A4 (b). The curves were automatically 
fitted using nonlinear regression and the Michaelis–Menten equation, 
and the data were obtained in triple experiments
Fig. 3 Effects of specific inhibitors on CYP‑mediated STS (10 µM) 
metabolism in HLMs. The concentration of CHL was 5 µM, while that 
for the other specific inhibitors was 1 µM. Each data point represents 
the mean ± SD of triple determinations (n = 3). In the presence of 
KET (1 µM), the MCR of STS decreased to 27.28 % of the control value, 
while the other inhibitors had no significant inhibitory effects on the 
metabolism of STS. FUR furafylline, specific inhibitor of CYP1A2; TRA 
trans‑2‑phenylcyclopropylamine, specific inhibitor of CYP2A6; SUL 
sulfaphenazole, specific inhibitor of CYP2C9; QUI quinidine, specific 
inhibitor of CYP2D6; CHL: chlormethiazole, specific inhibitor of 
CYP2E1; TICticlopidine, specific inhibitor of CYP2C19; KET ketocona‑
zole, specific inhibitor of CYP3A4
Fig. 4 Effects on the MCR of STS under inhibition of CYP3A4 by KET 
(1 µM). STS (10 or 50 μM) was incubated with CYP3A4 and cofactors 
in the absence (control) or presence of KET. Each point represents the 
mean ± SD of triple incubations. The MCR of STS was significantly 
decreased compared with the control value for CYP3A4, for both 
concentrations of STS
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Estimation of IC50 and Ki values
The inhibitory effects of multiple concentrations of STS 
(1–100  µM) on the activity of each CYP isoform were 
determined by metabolism of a single concentration of 
isoform-specific probe with HLMs (or expressed CYPs, 
when needed). STS showed potent inhibition of CYP3A4 
(midazolam 1-hydroxylation), with an IC50 of 6.4  µM. 
The inhibitory effects of STS on the activities of CYP1A2, 
CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP2C19 
were negligible (Fig.  5); therefore, we did not calculate 
the IC50 or Ki values for these enzymes related to STS.
Discussion
According to Jeong et  al. [30], IC50 values are qualita-
tively informative and helpful for addressing whether 
inhibition has occurred, but are of limited quantitative 
use because they can be influenced by the substrate con-
centration selected. Hence, it might not be accurate to 
use these parameters for quantitative prediction of drug 
interactions in vivo. Therefore, we performed additional 
experiments designed to estimate the Ki values. The pre-
liminary inhibition data generated from a single probe 
substrate reaction were used to simulate the appropriate 
range of substrate and inhibitor concentrations for use in 
the construction of Dixon plots for inhibition of the CYP 
isoforms by STS in HLMs, from which precise Ki values 
were estimated.
For CYP3A4, the Ki values were determined by mida-
zolam as the probe substrate. Among all of the CYPs 
tested, CYP3A4 was the most sensitive to inhibition by 
STS (Table 2). Representative Dixon plots for the inhibi-
tion of CYP3A4 in HLMs were shown in Fig.  6. Visual 
inspection of the Dixon plots and further analysis of the 
parameters of the enzyme inhibition models suggested 
that the inhibition data fitted well to a competitive type 
of inhibition (Fig. 7). The Ki values estimated by a non-
linear regression model for competitive enzyme inhibi-
tion of CYP3A4-catalyzed midazolam 1-hydroxylation in 
HLMs were less than 5 µM (Table 2, Fig. 7).
According to Kong et  al. [31], the potency of a test 
compound could be classified according to its IC50 val-
ues, as follows: potent, if IC50 is ≤20 μg/mL or ≤10 μM; 
moderate, if IC50 is 20–100  μg/mL or 10–50  μM; and 
weak, if IC50 is ≥100 μg/mL or ≥50 μM. Thus, STS was a 
potent inhibitor for CYP3A4 and a weak inhibitor for the 
other six CYPs tested in this study.
Although STS was a potent inhibitor of CYP3A4, the 
IC50 value of CYP3A4 for midazolam 1-hydroxylation 
was 26.6–79.7-fold higher and the Ki value was approxi-
mately 212-fold higher than that of KET in HLMs com-
pared with a previous study [26] (Table 2), indicating that 
the inhibitory effect of STS on CYP3A4 was much less 
than that of KET.
a
b
Fig. 5 Effects of STS on the metabolic reactions of the seven CYP 
specific substrates in HLMs (a) and the representative IC50 plots of 
STS on midazolam 1‑hydroxylation for CYP3A4 (b). Each data point 
represents the mean ± SD of triple determinations
a
b
Fig. 6 Non‑linear regression and double reciprocal (Lineweaver–
Burk) plots for direct inhibition of midazolam 1‑hydroxylation by 
different concentrations of STS (0–100 μM) in HLM incubations 
(0.5 mg protein/mL). The inhibition of CYP3A4 activity by STS can be 
best‑described as full competitive inhibition. Each data point is the 
mean of triple incubations
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Although the molecular structural difference between 
STS and tanshinone IIA is only the presence of a sulfonic 
acid group bond at the C-16 position [22], it resulted in a 
difference in inhibition of CYP activity. Wang et al. [32] 
reported that tanshinone IIA was a potent competitive 
CYP1A2 inhibitor with Ki values of 1.45 μM for pooled 
HLMs and 0.05  μM for a specific human CYP1A2 iso-
form, and a medium competitive inhibitor of CYP2C9. In 
this study, STS was a potent competitive CYP3A4 inhibi-
tor with a Ki value of 3.2 μM for pooled HLMs, but was 
not an inhibitor of CYP1A2.
The CYP3A4 enzyme, one of the dominant CYP 
enzymes in both the liver and extrahepatic tissues such 
as the intestine, plays an important role in the oxidation 
of xenobiotics and contributes to the biotransformation 
of about 60  % of currently used therapeutic drugs [33]. 
Human CYP3A4 is one of the most abundant drug-
metabolizing P450 isoforms in HLMs, and accounts 
for approximately 40  % of the total P450 activity [32]. 
Because STS was a potent inhibitor of CYP3A4 and given 
that CYP3A4 is responsible for the metabolism and dis-
position of a large number of currently used drugs, the 
potential herb–drug interactions of STS with drugs that 
were substrates of CYP3A4 or drugs with a narrow thera-
peutic index could not be negligible in the clinic. The 
present study supports the notion that STS is a substrate 
of CYP3A4 alone, while the issue of whether STS may 
be metabolized by other enzyme systems, such as more 
complex in vitro systems (hepatocytes for instance) that 
are not present (or functional in microsomes) remains 
unclear. Therefore, the present data do not support that 
STS would be a victim of drug–drug interactions (DDIs) 
by other CYP3A4 inhibitors, and further studies are 
required to elucidate this point.
Although STS in the form of injections is often used 
in clinical settings, pharmacokinetics studies in humans 
were lacking. Meanwhile, (Additional file 1) pharmacoki-
netics studies [15, 16] of STS in rats indicated that STS 
was widely distributed in most tissues after intravenous 
administration (2 mg/kg), and that it was mainly cleared 
via both the liver and kidney. The maximal STS concen-
tration (>10 μg/mL) was found in the liver at 5 min after 
drug administration, subsequently declined progressively 
during 30  min, and then decreased quickly over time 
thereafter. STS could be determined at 12 and 4 h after 
drug administration in the liver and kidney, respectively. 
STS was hardly detected at 2 h after drug administration 
in other tissues [15, 16]. Therefore, co-administered med-
icines were suggested to be given at least 2  h after STS 
administration to avoid the risk of DDIs with STS.
Genetic variations in the CYP3A4 gene may influence 
the level or function of the CYP3A4 protein, and more 
than 30 single nucleotide polymorphisms (SNPs) have 
been identified in the CYP3A4 gene [34]. In previous 
studies, allelic variants in the gene encoding CYP3A4 
were shown to affect enzyme activities, such as obser-
vations that variant CYP3A4 forms T363  M (<40  %) 
and T185S (<60  %) reduced testosterone 6β- and 
2β-hydroxylase activities compared with the wild-type 
enzyme [35], while some SNPs in the CYP3A4 gene such 
as CYP3A4*1B and CYP3A4*22 were reported to affect 
the pharmacokinetics of tacrolimus [36]. However, the 
issue of whether genetic polymorphisms of CYP3A4 can 
affect the DDIs of STS requires further study for clarifica-
tion in the future.
Conclusion
This in vitro study showed that STS mainly inhibited the 
activities of CYP3A4.
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